Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance

Heron Therapeutics IncTrade
KraneShares CSI China Internet ETFTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs KraneShares CSI China Internet ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while KraneShares CSI China Internet ETF trades at $27.11. The key difference: KraneShares CSI China Internet ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXKWEB
Market Cap
$91.46M
Sector
HealthSector/Thematic
52-Week High
$1.96$42.94
52-Week Low
$0.39$23.63
Enterprise Value
$189.36M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

KraneShares CSI China Internet ETF

KWEB, the KraneShares CSI China Internet ETF, trades at $27.44, up 2.35% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers exposure to leading Chinese internet and AI companies, currently near 52-week lows. Recent news highlights China's AI investment plans and factory rebound driven by AI hardware exports, providing potential growth catalysts amid economic stabilization efforts.

The outlook for KWEB is cautiously optimistic, with attractive valuations relative to Western peers and strong AI-driven growth potential. Key risks include US-China tensions, regulatory changes, and economic volatility. Analyst sentiment is mixed, balancing long-term value against near-term geopolitical and market uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About KraneShares CSI China Internet ETF

KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.

Read more on KWEB